$88m raised by a rna therapeutic platform play:
In addition to the pharmacological kinetics, King highlighted the biodistribution aspect of the platform. Even beyond ALS and motor neuron disease, “Penetrating deep brain tissues with [ASOs] opens up a whole new field of neurodegenerative diseases that could be treated,” he said.
King said he sees QurAlis as a platform company, particularly highlighting FlexASO.
The company closed a$42 million Series Ain May 2020.“[QurAlis has] a very strong focus on genetically validated targets and a very biomarker-driven development strategy, and this is exactly how we feel precision medicines should be developed for neurodegenerative diseases like ALS,” King toldBioSpaceprior to the announcement.
interesting article worth are read about clinical stage CNS ASO play:
https://www.biospace.com/article/quralis-biomarker-driven-approach-attracts-88m-in-series-b-/
$88m raised by a rna therapeutic platform play:In addition to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |